FISCHER
FISCHER MEDICAL VENTURE L
Each stock's 10,000-path forecast, rendered as light.
FISCHER MEDICAL VENTURE L (FISCHER) Stock Analysis & Case Study
Is FISCHER a good buy? The data-driven verdict.
FISCHER MEDICAL VENTURE L (FISCHER) trades at ₹35,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 22/100.
On the numbers, FISCHER MEDICAL VENTURE L (FISCHER) high-risk on the numbers, a Downstox Snapshot Score of 22/100, weighing expensive at 74.0× earnings, ROE of 8.6%, a 4% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
FISCHER fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is FISCHER overvalued? FISCHER P/E vs its sector
FISCHER's P/E of 74.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.01% dividend yield is below the peer median of 1.65%.
FISCHER share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 0.9y of FISCHER history (-83%/yr drift, 58%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| FISCHER 2027 | ₹6 | ₹13 | ₹28 | -63% |
| FISCHER 2028 | ₹2 | ₹5 | ₹14 | -86% |
| FISCHER 2029 | ₹1 | ₹2 | ₹7 | -95% |
| FISCHER 2030 | ₹0 | ₹1 | ₹3 | -98% |
| FISCHER 2031 | ₹0 | ₹0 | ₹1 | -99% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability FISCHER goes up, or doubles?
The bull case for FISCHER
- FISCHER MEDICAL VENTURE L is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹7.
The bear case & risks
- A rich 74.0× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 8.6%, capital efficiency trails higher-quality peers.
- The probability model is cautious 12 months out, only a 4% chance of finishing above today's price.
- High historical volatility (58%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1.
FISCHER volatility & expected range, how bumpy is the ride?
Over the last 0.9 years FISCHER compounded at -83%/year with annualized volatility of 58%. That volatility implies a 1-year 80% range of ₹6–₹28, the honest backbone behind any single price target.
FISCHER price forecast, the full 60-month probability fan
FISCHER price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds FISCHER hits common targets within the simulated horizon?
Full multi-horizon detail on the FISCHER price target & forecast page.
FISCHER Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. FISCHER scores 4/9,mixed financial health.
FISCHER MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy FISCHER with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 38.9% | 2.6× |
| Zerodha | 50.0% | 2.0× |
Compare every broker on the FISCHER MTF page.
FISCHER vs peers,sector comparison
About FISCHER MEDICAL VENTURE L: sector, index & market-cap context
FISCHER MEDICAL VENTURE L (FISCHER) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹2,295 Cr. See more Nifty 500 stocks.
How the FISCHER Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of FISCHER MEDICAL VENTURE L's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
FISCHER analysis, FAQs
Is FISCHER MEDICAL VENTURE L (FISCHER) a good buy?
On the numbers, FISCHER MEDICAL VENTURE L (FISCHER) high-risk on the numbers, a Downstox Snapshot Score of 22/100, weighing expensive at 74.0× earnings, ROE of 8.6%, a 4% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is FISCHER overvalued or undervalued?
FISCHER trades at 74.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the FISCHER share price target for 2031?
FISCHER's probability-weighted 2031 median target is ₹0, with an 80% range of ₹0–₹1 (10,000-path Monte-Carlo).
What is the probability FISCHER doubles in 5 years?
The modelled probability of FISCHER reaching ₹72 (2×) within 5 years is 0%.
What is the bull case for FISCHER?
FISCHER MEDICAL VENTURE L is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in FISCHER?
A rich 74.0× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 8.6%, capital efficiency trails higher-quality peers. The probability model is cautious 12 months out, only a 4% chance of finishing above today's price.